Breaking News
Get 55% Off 0
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.
See Undervalued Shares
Close

GlaxoSmithKline PLC (G1SK34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
42.80 -1.00    -2.28%
07:58:59 - Closed. Currency in BRL
  • Volume: 33
  • Bid/Ask: 32.99 / 43.80
  • Day's Range: 42.80 - 42.80
Type:  Equity
Market:  Brazil
ISIN:  BRG1SKBDR008 
GlaxoSmithKline 42.80 -1.00 -2.28%

GlaxoSmithKline PLC Company Profile

 
Get an in-depth profile of GlaxoSmithKline PLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

70212

Equity Type

DRC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson’s disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Contact Information

Address 980 Great West Road Middlesex
Brentford, TW8 9GS
United Kingdom
Phone 44 20 8047 5000
Fax -

Top Executives

Name Age Since Title
Emma Natasha Walmsley 53 2011 CEO & Director
Jonathan Richard Symonds 64 2019 Non-Executive Chairman
Anne C. Beal 61 2021 Independent Non-Executive Director
Harry C. Dietz 65 2022 Independent Non-Executive Director
Elizabeth McKee Anderson 66 2022 Independent Non-Executive Director
Jesse L. Goodman 71 2016 Independent Non-Executive Director
Julie Brown 61 2023 CFO & Executive Director
Hal V. Barron 60 2018 Non-Executive Director
Vishal Sikka 56 2022 Independent Non-Executive Director
Charles A. Bancroft 65 2020 Senior Independent Non-Executive Director
Wendy Becker 59 2023 Independent Non-Executive Director
Tsun-Huei Lee 60 2024 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

G1SK34 Comments

Write your thoughts about GlaxoSmithKline PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email